Squamous Cell Skin Carcinoma Clinical Trials

Find Squamous Cell Skin Carcinoma Clinical Trials Near You

Feasibility Study of Cemiplimab and Quad Shot Radiation in Elderly, Frail, or High Comorbidity Patients With Locally Advanced Cutaneous Squamous Cell Carcinomas of the Skin Arising in the Head and Neck Region

Status: Recruiting
Location: See location...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The goal of this clinical trial is to learn if the combination of the drug cemiplimab along with a short course of radiation therapy called Quad Shot can be successfully given in several rounds to elderly or frail patients with head and neck skin cancers. The main question it aims to answer is: \- Can care providers successfully deliver at least 6 rounds of cemiplimab and 3 rounds of Quad Shot radiation to patients? Patients will: * Be given cemiplimab every 3 weeks for a total of up to 8 doses * Be given Quad Shot radiation (four treatments over two days) every 3 weeks for a total of up to 4 rounds

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Locally advanced squamous cell carcinoma of the skin arising from the head and neck region.

• Patients who have had prior treatment of a localized skin primary and now present with nodal recurrence or unresectable local recurrence are considered eligible as long as the recurrent disease has not been previously treated with radiation therapy

• No prior systemic therapy including chemotherapy, targeted therapy or immunotherapy.

• Deemed unfit for definitive curative intent treatment with surgery or radiation therapy due to one of the following criteria:

‣ ECOG Performance status 3 or 4;

⁃ significant co-morbid medical conditions.

⁃ frailty due to advanced age (must be \> 70 years of age if using this criterion only).

• At least one measurable lesion as defined by RECIST 1.1.

• Tumor tissue available for correlative-sequencing (tumor tissue from bony metastasis is not suitable; however, archival tissue is acceptable). A minimum of 6 cores from initial lymph node biopsy is strongly encouraged.

• Adequate organ function as defined by:

• • Absolute neutrophil count \>= 1,000/ul

⁃ Platelets \>= 75,000/ul

⁃ Hemoglobin \>= 7 g/dL (without requirement for transfusion in prior 4 weeks)

⁃ Calculated serum creatinine clearance \> 20 mL/min by the Cockcroft-Gault formula (clearance \< 20mL/min will be allowed if patient is on a stable dialysis regimen)

⁃ Total bilirubin =\< 1.5 X upper normal limit (UNL) (except subjects with Gilbert syndrome, who can have total bilirubin \< 3 mg/dl)

⁃ Aspartate aminotransferase (AST) =\< 3.0 X UNL

⁃ Alanine aminotransferase (ALT) =\< 3.0 X UN

• Willing and able to sign informed consent.

• Male or female ≥ 18 years of age at the time of informed consent.

⁃ Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during screening and prior to receiving first dose of protocol-indicated treatment.

∙ Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal.

‣ Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 years of age in the absence of other biological or physiological causes.

‣ Women of childbearing potential must agree to use of contraceptives to prevent pregnancy.

Locations
United States
Missouri
Washington University Medical Center
RECRUITING
St Louis
Contact Information
Primary
Barbara Murphy, M.D.
barbara.murphy@vumc.org
615-936-8422
Backup
Zachary Kohutek, M.D., Ph.D.
zachary.a.kohutek@vumc.org
615-591-9890
Time Frame
Start Date: 2026-09
Estimated Completion Date: 2029-09
Participants
Target number of participants: 25
Treatments
Experimental: Cemiplimab and radiation
Related Therapeutic Areas
Sponsors
Leads: Vanderbilt-Ingram Cancer Center
Collaborators: Regeneron Pharmaceuticals

This content was sourced from clinicaltrials.gov